Mega Lifesciences 과거 순이익 실적
현재 이 회사의 최신 실적 보고서를 처리하고 있습니다
과거 기준 점검 4/6
Mega Lifesciences은 연평균 1%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 8.3% 증가했습니다. 매출은 연평균 0.9%의 비율로 증가했습니다. Mega Lifesciences의 자기자본이익률은 19.7%이고 순이익률은 14.4%입니다.
핵심 정보
1.00%
순이익 성장률
1.00%
주당순이익(EPS) 성장률
| Pharmaceuticals 산업 성장률 | 12.39% |
| 매출 성장률 | 0.86% |
| 자기자본이익률 | 19.67% |
| 순이익률 | 14.35% |
| 다음 순이익 업데이트 | 01 Sep 2026 |
최근 과거 실적 업데이트
Recent updates
내러티브 업데이트 • Jun 24
MEGA: Higher Margins And Lower Growth Will Likely Keep Shares Fairly Valued
Analysts have kept their fair value estimate for Mega Lifesciences steady at THB35.0, explaining that slightly softer revenue growth assumptions are offset by a higher profit margin outlook and a marginally lower future P/E multiple in their updated price target work. What’s in the News for Mega Lifesciences No recent company specific news items for Mega Lifesciences were identified in the provided sources.
내러티브 업데이트 • Jun 07
MEGA: Stable Assumptions And Margin Outlook Will Drive Future Upside
Analysts have kept their price target for Mega Lifesciences unchanged at THB 41.14, citing only small adjustments to projected revenue growth, profit margins and future P/E assumptions that do not materially alter their overall view of the stock. What's in the News No recent company specific news for Mega Lifesciences has been provided in the available sources.내러티브 업데이트 • May 24
MEGA: Higher Margin Outlook And Dividend Decision Will Support Future Upside
Analysts have trimmed their price target for Mega Lifesciences slightly to THB 41.14 from THB 41.17, reflecting updated assumptions that now pair a lower revenue growth outlook of 4.12% with a higher projected profit margin of 16.40% and a modestly lower future P/E of 16.67x. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).내러티브 업데이트 • May 06
MEGA: Stable Outlook And Upcoming Dividend Decision Will Drive Further Upside
Analysts have kept their fair value estimate for Mega Lifesciences steady at THB41.17 per share, with only minimal model tweaks related to the discount rate, profit margin outlook and future P/E assumptions. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).내러티브 업데이트 • Apr 21
MEGA: Higher Growth And Lower Margins Will Likely Keep Shares Fairly Valued
Analysts have lifted their price target on Mega Lifesciences from THB 32 to THB 35, citing updated assumptions around higher revenue growth, a slightly lower discount rate and a revised future P/E multiple, partially offset by a more conservative profit margin outlook. What's in the News Board meeting scheduled for Feb 24, 2026, to consider a dividend payment proposal for the year ended Dec 31, 2025 (company filing).내러티브 업데이트 • Apr 06
MEGA: Stable Outlook And Upcoming Dividend Decision Will Support Upside
Analysts have maintained their price target for Mega Lifesciences at THB41.17, citing unchanged assumptions regarding fair value, discount rate, revenue growth, profit margin, and future P/E. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).내러티브 업데이트 • Mar 23
MEGA: Higher Fair Value And Upcoming Dividend Decision Will Support Upside
Analysts have lifted their fair value estimate for Mega Lifesciences from THB 38.21 to THB 41.17, citing updated assumptions for long term profit margins and a higher future P/E multiple. What's in the News A board meeting is scheduled for February 24, 2026 for Mega Lifesciences Public Company Limited.
내러티브 업데이트 • Mar 09
MEGA: Higher Future P/E Will Support Upgraded Fair Value Outlook
Analysts have lifted their price target for Mega Lifesciences from THB 41.60 to THB 45.00. They highlighted updated assumptions that include slightly lower revenue growth and profit margins, together with a higher future P/E multiple.내러티브 업데이트 • Feb 23
MEGA: Updated Discount Rate And Margins Will Support Fair Pricing Ahead
Analysts have raised their price target on Mega Lifesciences to THB 38.21 from THB 34.58, citing updated assumptions related to slightly lower discount rates, adjusted revenue growth, modestly different profit margins and a revised future P/E multiple. Valuation Changes Fair Value: THB 34.58 to THB 38.21, indicating a modest uplift in the assessed share valuation.내러티브 업데이트 • Feb 09
MEGA: Fair Outlook Will Balance Softer Margins With Stronger Revenue Expectations
Narrative update on Mega Lifesciences The analyst price target for Mega Lifesciences has been lifted from ฿39.00 to ฿41.60, with analysts linking this change to updated assumptions for slightly lower discount rates, higher forecast revenue growth, a modestly softer profit margin, and a higher future P/E multiple. Valuation Changes Fair Value Estimate: Raised from THB 39.00 to THB 41.60, a small uplift in the assessed equity value.내러티브 업데이트 • Jan 25
MEGA: Stable Assumptions And Margins Will Support Fair Pricing Ahead
The analyst price target for Mega Lifesciences remains unchanged at ฿34.58, with analysts citing consistent assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. Valuation Changes Fair value: Unchanged at THB34.58 per share, with no adjustment to the underlying assumptions.내러티브 업데이트 • Jan 10
MEGA: Higher Margin Assumptions Will Likely Leave Shares Overvalued
The analyst fair value estimate for Mega Lifesciences has been adjusted from ฿26.00 to ฿32.00, with analysts pointing to updated assumptions around revenue growth, profit margins and forward P/E to support the higher target. Valuation Changes The fair value estimate has risen from THB 26.00 to THB 32.00 per share, reflecting updated assumptions in the model.내러티브 업데이트 • Dec 24
MEGA: Stable Margins And Earnings Outlook Will Support Fair Pricing Ahead
Analysts have reaffirmed their price target on Mega Lifesciences at THB 34.58 per share, citing unchanged assumptions for discount rate, revenue growth, profit margins, and future valuation multiples, which together support a steady outlook for the company’s fair value. Valuation Changes Fair Value: Unchanged at approximately THB 34.58 per share, indicating no revision to the overall equity valuation.내러티브 업데이트 • Dec 09
MEGA: Stable Margins And Earnings Outlook Will Support Fair Pricing Ahead
Analysts have maintained their price target on Mega Lifesciences at THB 34.58 per share, reflecting steady assumptions on revenue growth, profit margins, and valuation multiples despite the latest review of fundamentals. Valuation Changes Fair Value: Unchanged at approximately THB 34.58 per share, indicating no revision to the core valuation thesis.내러티브 업데이트 • Nov 25
MEGA: Improved Profit Margins And Revenue Estimates Suggest Fair Valuation Ahead
Analysts have raised their price target for Mega Lifesciences from THB 32.14 to THB 34.58. This reflects improved revenue growth forecasts and a slightly stronger profit margin outlook.새로운 내러티브 • Jun 01
Expansion In Indonesia And Vietnam Will Fuel Emerging Wellness Markets
Strategic expansion in high-growth markets and local manufacturing reduce operational risks and support sustainable revenue and margin growth.매출 및 비용 세부 내역
매출 및 비용 세부 내역
Mega Lifesciences가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 31 Mar 26 | 14,399 | 2,067 | 4,467 | 0 |
| 31 Dec 25 | 14,195 | 1,912 | 4,481 | 0 |
| 30 Sep 25 | 14,191 | 1,974 | 4,386 | 0 |
| 30 Jun 25 | 14,312 | 1,863 | 4,383 | 0 |
| 31 Mar 25 | 14,859 | 1,985 | 4,382 | 0 |
| 31 Dec 24 | 15,385 | 2,012 | 4,385 | 0 |
| 30 Sep 24 | 15,882 | 1,846 | 4,410 | 0 |
| 30 Jun 24 | 15,685 | 1,999 | 4,331 | 0 |
| 31 Mar 24 | 15,718 | 2,017 | 4,230 | 0 |
| 31 Dec 23 | 15,716 | 1,993 | 4,191 | 0 |
| 30 Sep 23 | 15,442 | 1,919 | 4,278 | 0 |
| 30 Jun 23 | 15,693 | 2,042 | 4,352 | 0 |
| 31 Mar 23 | 15,634 | 2,081 | 4,398 | 0 |
| 31 Dec 22 | 15,727 | 2,242 | 4,359 | 0 |
| 30 Sep 22 | 15,116 | 2,338 | 4,068 | 0 |
| 30 Jun 22 | 15,061 | 2,292 | 4,054 | 0 |
| 31 Mar 22 | 14,724 | 2,227 | 3,924 | 0 |
| 31 Dec 21 | 14,172 | 1,947 | 3,769 | 0 |
| 30 Sep 21 | 14,395 | 1,878 | 3,767 | 0 |
| 30 Jun 21 | 13,775 | 1,607 | 3,538 | 0 |
| 31 Mar 21 | 12,809 | 1,406 | 3,331 | 0 |
| 31 Dec 20 | 12,613 | 1,393 | 3,288 | 0 |
| 30 Sep 20 | 12,168 | 1,348 | 3,169 | 0 |
| 30 Jun 20 | 11,642 | 1,288 | 3,137 | 0 |
| 31 Mar 20 | 11,655 | 1,205 | 3,195 | 0 |
| 31 Dec 19 | 11,164 | 1,139 | 3,176 | 0 |
| 30 Sep 19 | 10,950 | 1,163 | 3,198 | 0 |
| 30 Jun 19 | 10,712 | 1,136 | 3,153 | 0 |
| 31 Mar 19 | 10,569 | 1,203 | 3,113 | 0 |
| 31 Dec 18 | 10,284 | 1,206 | 3,052 | 0 |
| 30 Sep 18 | 10,147 | 1,183 | 3,041 | 0 |
| 30 Jun 18 | 9,937 | 1,175 | 3,010 | 0 |
| 31 Mar 18 | 9,829 | 1,178 | 2,988 | 0 |
| 31 Dec 17 | 9,624 | 1,113 | 2,965 | 0 |
| 30 Sep 17 | 9,514 | 1,023 | 2,928 | 0 |
| 30 Jun 17 | 9,282 | 945 | 2,869 | 0 |
| 31 Mar 17 | 8,968 | 873 | 2,766 | 0 |
| 31 Dec 16 | 8,828 | 795 | 2,674 | 0 |
| 30 Sep 16 | 8,514 | 771 | 2,603 | 0 |
| 30 Jun 16 | 8,226 | 756 | 2,658 | 0 |
| 31 Mar 16 | 8,115 | 703 | 2,714 | 0 |
| 31 Dec 15 | 7,966 | 696 | 2,718 | 0 |
| 30 Sep 15 | 7,775 | 675 | 2,668 | 0 |
양질의 수익: MEGA는 고품질 수익을 보유하고 있습니다.
이익 마진 증가: MEGA의 현재 순 이익률 (14.4%)은 지난해 (13.4%)보다 높습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: MEGA의 수익은 지난 5년 동안 연평균 1% 증가했습니다.
성장 가속화: 지난 1년간 MEGA 의 수익 증가율(4.1%)은 연간 평균(1%)을 초과합니다.
수익 대 산업: MEGA의 지난 1년 수익 증가율(4.1%)은 Pharmaceuticals 업계 평균(10.1%)을 능가하지 못했습니다.
자기자본이익률
높은 ROE: MEGA의 자본 수익률(19.7%)은 낮음으로 평가됩니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/08/14 02:56 |
| 종가 | 2026/08/14 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Mega Lifesciences Public Company Limited는 15명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Thanapol Jiratanakij | CGS International |
| Chanpen Sirithanarattanakul | DBS Bank Ltd |
| Nantika Wiangphoem | DBS Bank Ltd |